Researchers have identified several peptide-based compounds that could potentially block a key enzyme used by the COVID-19 virus, according to a new study published in Scientific Reports.
The study focused on the SARS-CoV-2 papain-like protease (PLpro), an enzyme essential for viral replication and its ability to weaken the body’s immune response. Scientists used computer-based methods to screen more than 6,600 antimicrobial peptides for their ability to bind to and inhibit this target.
From this large dataset, a small number of candidates showed promising results. In particular, peptides labelled 17,047 and 33,035 demonstrated strong predicted interactions with the enzyme’s active site. These interactions could potentially block the enzyme’s function, slowing or stopping the virus from replicating.
The research relied on molecular docking and simulation techniques to analyse how the peptides interact with PLpro. The findings suggested that peptide 17,047 showed stable binding behaviour and was predicted to be non-toxic, making it the most promising candidate for further study. Peptide 33,035 showed stronger binding but raised concerns over possible toxicity, meaning it may require further modification.
PLpro plays a dual role in the virus. It helps process viral proteins needed for replication and also interferes with the host’s immune signalling pathways. Because of this, it is considered an important target for antiviral drug development alongside other viral proteins.
The study also compared the peptide candidates with known inhibitors and small-molecule drugs. While peptides showed strong interaction potential, researchers noted challenges such as stability, delivery into cells, and possible side effects. These factors must be addressed before any clinical use.
The authors stressed that the findings are based on computational models and not laboratory or clinical testing. Further experimental studies, including biochemical assays and antiviral testing, will be required to confirm whether these peptides are effective and safe in real-world conditions.
Peptide-based therapies are an emerging area of research due to their ability to target specific biological processes. However, experts note that translating early computational results into approved medicines remains a complex and time-consuming process.